Key facts
- This page summarizes Anthony Doyle's Form 4 filing for BIOCRYST PHARMACEUTICALS INC (BCRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 19 Dec 2022, 15:55.
Anthony Doyle - 15 Dec 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- BCRX
- Reported as of
- 15 Dec 2022
- Net transaction value
- -$62,130
- SEC form
- 4
- Accepted by SEC
- 19 Dec 2022, 15:55:39 UTC
- Prior SEC filing
- 13 Jan 2022
- Next SEC filing
- 21 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alane P. Barnes, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Anthony Doyle filed Form 4 for BIOCRYST PHARMACEUTICALS INC (BCRX) on 19 Dec 2022.
Change
- Previous filing in this sequence was filed on 13 Jan 2022.
- Current net transaction value: -$62,130.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BCRX
transaction
Common Stock
Sale
- Transaction value
- $62,130
- Shares
- -5,700
- Change %
- -3.4%
- Price
- $10.90
- Shares after
- 163,966
- Date
- 15 Dec 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2022 to cover tax withholding obligations in connection with the vesting of 18,750 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Footnote F2
The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.50 to $11.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.